Table 1 Prevalence of polypharmacy and of the main drugs prescribed, Colaus study, Switzerland, 2009–2012, 4938 participants
From: Prevalence and determinants of polypharmacy in Switzerland: data from the CoLaus study
Frequency n (%) | 95% CI | |
|---|---|---|
Any drug | 2947 (59.7) | (58.3–61.1) |
Polypharmacy (≥5 drugs) | 580 (11.8) | (10.9–12.7) |
Excessive polypharmacy (≥10 drugs) | 69 (1.4) | (1.1–1.8) |
Cardiovascular | 1843 (37.3) | (36.0–38.7) |
Antihypertensive drugs | 1327 (26.9) | (25.6–28.1) |
Angiotensin receptor blockers | 644 (13.0) | (12.1–14.0) |
Beta-blockers | 444 (9.0) | (8.2–9.8) |
Angiotensin converting enzyme inhibitors | 350 (7.1) | (6.4–7.8) |
Calcium channel blockers | 229 (4.6) | (4.1–5.3) |
Diuretics | 158 (3.2) | (2.7–3.7) |
Other | 81 (1.6) | (1.3–2.0) |
Hypolipidemic drugs | 1029 (20.8) | (19.7–22.0) |
Statins | 861 (17.4) | (16.4–18.5) |
Other hypolipidemic drugs | 219 (4.4) | (3.9–5.0) |
Antiplatelet drugs | 572 (11.6) | (10.7–12.5) |
Aspirin | 527 (10.7) | (9.8–11.6) |
Vitamin K antagonists | 108 (2.2) | (1.8–2.6) |
Psychiatric | 781 (15.8) | (14.8–16.9) |
Antidepressants | 516 (10.5) | (9.6–11.3) |
Anxiolytics | 243 (4.9) | (4.3–5.6) |
Hypnotics and sedatives | 230 (4.7) | (4.1–5.3) |
Antipsychotics | 54 (1.1) | (0.8–1.4) |
Analgesics | 657 (13.3) | (12.4–14.3) |
Anilides | 110 (2.2) | (1.8–2.7) |
Non-steroidal anti-inflammatory drugs | 447 (9.1) | (8.3–9.9) |
Opioids | 61 (1.2) | (0.9–1.6) |
Vitamins and minerals | 616 (12.5) | (11.6–13.4) |
Gastro-intestinal Drugs | 469 (9.5) | (8.7–10.3) |
Antiacids | 351 (7.1) | (6.4–7.9) |
Drugs for constipation | 68 (1.4) | (1.1–1.7) |
Othera | 114 (2.3) | (1.9–2.8) |
Antidiabetic drugs | 274 (5.6) | (4.9–6.2) |
Oral antidiabetics | 252 (5.1) | (4.5–5.8) |
Insulin | 59 (1.2) | (0.9–1.5) |